ECS OPCO 1, LLC – Trademark Portfolio

Entity Type: 16

ECS OPCO 1, LLC holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 8 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 4 trademarks are registered and 4 are pending. Notable registered marks include C3 WAVE, MORPHEUS, TURBO-JECT, and VENTRICLEAR. The owner is based in WHITE PLAINS, NY.

50 MAIN STREET

SUITE 1013

WHITE PLAINS, NY 10606

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

ECS OPCO 1, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (8 filings)

Surgical, medical, dental and veterinary apparatus and instruments

42
Computer & Scientific (3 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does ECS OPCO 1, LLC have?

ECS OPCO 1, LLC has 8 U.S. trademarks filed with the USPTO. Of these, 4 registered, 4 pending.

What trademark classes does ECS OPCO 1, LLC file in?

ECS OPCO 1, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are ECS OPCO 1, LLC's most well-known trademarks?

ECS OPCO 1, LLC's registered trademark portfolio includes well-known marks such as C3 WAVE, MORPHEUS, TURBO-JECT, and VENTRICLEAR. These are among 4 currently registered trademarks in the portfolio.

What is ECS OPCO 1, LLC's trademark registration success rate?

ECS OPCO 1, LLC has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 4 applications are pending review.